ABUS — Arbutus Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $490.08m
- $364.07m
- $18.14m
Annual cashflow statement for Arbutus Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -154 | -63.7 | -76.2 | -69.5 | -72.8 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 95.6 | 9.89 | 6.03 | 3.43 | 3.74 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.23 | 0.432 | 0.93 | 29.2 | -18.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -71 | -51.4 | -67.5 | -35.4 | -85.9 |
| Capital Expenditures | -0.589 | -0.229 | -0.809 | -0.512 | -1.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 28.9 | -14.7 | -11.9 | -74.4 | 51.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 28.3 | -14.9 | -12.7 | -74.9 | 50.8 |
| Financing Cash Flow Items | 18.5 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 37.5 | 86.7 | 137 | 31.8 | 30.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.14 | 20.5 | 57 | -78.5 | -4.49 |